The present invention is directed to certain fused pyrimidines having a homo or hetero cyclopentyl, cyclohexyl or cycloheptyl ring as the pyrimidine fusion partner; having an amino benzyl or substituted amino benzyl group at the 4 position of the pyrimidine ring; and a 5:6 heterobicyclo ring with at least one N, O or S at the 2 position of the pyrimidine ring. These compounds are useful for treatment of cancer by inhibition of the p97 complex.
本发明涉及某些融合
嘧啶,其
嘧啶融合伙伴为同族或杂族环戊基、环己基或环庚基环;在
嘧啶环的 4 位上具有
氨基苄基或取代
氨基苄基;以及在
嘧啶环的 2 位上具有至少一个 N、O 或 S 的 5:6 杂双环。这些化合物通过抑制 p97 复合物可用于治疗癌症。